Nine hundred thirty-nine patients received induction therapy ( four @-day cycles pemetrexed @ mg/m and cisplatin @ mg/m ) , after which @ nonprogressing patients with an Eastern Cooperative Oncology Group performance status ( PS ) of @/@ were randomized ( @:@ ) to maintenance pemetrexed ( @ mg/m ) cycles or placebo until disease progression .